Pfizer (PFE), a global pharmaceutical giant that was once a pandemic darling, is now facing turbulence. Following a period of extraordinary vaccine-driven revenue, the company now faces a more ...

In an exclusive interview, Sally Susman, a pioneer in corporate comms, recounts finding out that Pfizer's COVID-19 vaccine was viable.

The Justice Department changed its policy on foreign corruption cases, which might have put an end to investigations into the pharmaceutical company.

The FDA plans to limit access to certain high-risk groups and also told Pfizer and Moderna to update their warning labels about heart inflammation.

Pfizer projects 2025 revenues of $61-$64 billion, adjusted EPS of $2.80-$3.00, and $24-$26 billion in combined SI&A and R&D expenses while reaffirming its 2024 guidance.

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

Pfizer said Tuesday it does not expect the Trump administration to make major changes to vaccine policy next year even with vaccine skeptic Robert F. Kennedy Jr. as the nominee to run the ...

In a year in which he withstood a challenge from an activist investor, Pfizer CEO Albert Bourla received a 14% pay raise to $24.6 million in 2024.

Activist investor Starboard Value has taken a $1 billion stake in beleaguered drugmaker Pfizer Inc. and is seeking a turnaround, the Wall Street Journal reported late Sunday. Citing unnamed ...

Pfizer CEO Albert Bourla, under pressure from activist hedge fund Starboard Value, made his case to Wall Street on Tuesday that the drugmaker's turnaround is succeeding after it reported a higher ...

Activist investor Starboard Value has taken a roughly $1 billion stake in Pfizer PFE-0.52%decrease; red down pointing triangle and wants the struggling drugmaker to make changes to turn its ...